US Corporate Board Director Changes SEC Filings — March 30, 2026

30-03-2026

Ensysce Biosciences, Inc. announced the resignation of Board Director Lee Rauch effective March 24, 2026, who chaired the Nominating and Corporate Governance Committee and served on the Audit and Compensation Committees, citing disagreements with Board actions including the approval of retention and severance packages. The Board approved three-month severance packages for three managers and extended CFO Mr. Humphrey's retention package from 6 to 9 months, totaling approximately $205,475, to preserve enterprise value amid strategic alternatives review. Ms. Rauch voted against the packages on March 23, 2026, highlighting internal discord.

• ·Resignation notice attached as Exhibit 17.
• ·Board approval of packages on March 27, 2026.

30-03-2026

On March 24, 2026, Noodles & Company Class I directors Robert Hartnett and Mary Egan notified the Board they will not stand for re-election at the 2026 Annual Meeting of Stockholders, continuing to serve until then with no disagreements with management or the Board. The Board voted to reduce its size from nine to seven members effective at the Annual Meeting to better align with company size and complexity, and nominated Mr. Lynch as a Class I director contingent on his election and resignation from Class III to rebalance board classes.

• ·Directors Hartnett and Egan's decisions to not stand for re-election were not due to any disagreement with management, Board, operations, policies, or practices.
• ·Annual Meeting date not specified; board changes effective upon its conclusion.

30-03-2026

Douglas G. Thompson resigned as CEO and Managing Director effective March 31, 2026, to pursue new opportunities, leading the Board to reduce its size from seven to six members. Garold Spindler, age 78 and current Executive Chair with extensive coal industry experience, was appointed Interim CEO effective April 1, 2026, under a new employment agreement with an annual base salary of $1,250,000. Additionally, Greg Pritchard was appointed Board Chair effective the same date.

• ·Mr. Thompson informed of resignation on February 22, 2026 (February 23 in Australia).
• ·Mr. Spindler previously served as CEO from August 2018 to May 2023.
• ·Employment agreement dated March 27, 2026; terminable with 30 days' notice; includes 1-year non-compete.
• ·No family relationships or related party transactions with Mr. Spindler.

30-03-2026

On March 30, 2026, Rocket Lab Corporation amended Sir Peter Beck's employment agreement, voluntarily reducing his annual base salary to $1.00 or the New Zealand statutory minimum, eliminating any expectation of annual bonuses, and securing a waiver of related claims. Additionally, Mr. Beck forfeited all 392,155 unvested RSUs to redirect capital toward company priorities and strategic R&D initiatives, emphasizing long-term shareholder value over short-term incentives.

• ·Amendment approved by the Compensation Committee of the Board of Directors.
• ·Changes do not trigger Good Reason under the Company’s Executive Severance Plan.

30-03-2026

Teladoc Health (NYSE: TDOC) appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors effective March 30, 2026, following the retirements of directors Eric Evans and Thomas McKinley and the recent appointment of Michael Smith. Ms. Salka, who during her 33-year tenure at AMN drove 26 acquisitions and grew revenue to over $5 billion, will serve on the board's audit and compensation committees. Chairman Kenneth H. Paulus highlighted her healthcare leadership and governance experience to support Teladoc's care delivery transformation.

• ·Susan Salka holds an MBA in Finance from San Diego State University and a BA in Accounting and Economics from Chadron State College.
• ·Investor contact: Michael Minchak (IR@teladochealth.com, 617-444-9612).
• ·Media contact: Lou Serio (PR@teladochealth.com, 202-569-9715).

30-03-2026

On March 25, 2026, SunPower Inc. held a Special Meeting of Stockholders, approving all six proposals, including the Second Amendment to the 2023 Equity Incentive Plan increasing shares reserved for issuance to 44,573,109. Stockholders also approved share issuances related to prior acquisitions, an additional $22,225,000 of 7.00% Convertible Senior Notes due 2029, increasing the White Lion Purchase Agreement commitment from $30.0 million to $55.0 million, and the Yorkville Standby Equity Purchase Agreement, with strong support across proposals (over 66 million votes for each). However, opposition was notable on Proposal 3 (3.05 million against), Proposal 5 (1.25 million against), and Proposal 6 (8.44 million against).

• ·Proposal 1 approved issuance of shares in excess of 3,333,334 related to September 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 2 approved shares issuable upon conversion of additional $22,225,000 7.00% Notes.
• ·Proposal 3 approved post-closing consideration shares in excess of 16,620,910 related to November 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 4 approved increase of White Lion commitment from $30.0 million to $55.0 million.
• ·Proposal 5 approved shares under Yorkville Purchase Agreement potentially exceeding 20% of outstanding Common Stock as of January 27, 2026.

30-03-2026

On March 25, 2026, Steven I-Fang Cheng resigned as a member of the Board of Directors and Chief Technology Officer of Advanced Biomed Inc., with the resignation not due to any disagreement on operations, policies, or practices. On the same date, the Board appointed Mingze Yin, the Company's Chief Financial Officer, as a new Director. There are no family relationships, arrangements, or disclosable transactions involving Mr. Yin under Item 404(a) of Regulation S-K.

• ·Filing date: March 30, 2026; Earliest event date: March 25, 2026
• ·Company CIK: 0001941029; EIN: 87-2177170; Incorporated in Nevada; Fiscal year end: June 30
• ·Principal executive offices: No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan; Phone: 886-6-3121716
• ·Emerging growth company: Yes; Common Stock (ADVB) registered on Nasdaq

30-03-2026

On March 24, 2026, the Compensation Committee of Assembly Biosciences, Inc. approved the 2026 Corporate Bonus Plan, effective January 1, 2026, to provide cash bonuses based on corporate and individual performance objectives for eligible employees, including named executive officers. Bonus targets are set at up to 75% of base salary for the CEO, 30%-55% for other executive participants, and up to 28% for non-executive participants, with payouts ranging from 0% to 150% of target and requiring employment through the payment date in the first quarter following the performance period. Separately, CEO Jason A. Okazaki's bonus target was increased from 60% to 65% of his base salary for fiscal year 2026.

• ·Corporate Objectives weighted 100% for CEO, 75% for C-Level/SVP/VP (with 25% individual), 50% for Director-level (50% individual), and 25% for Associate Director and below (75% individual).
• ·Corporate Objectives approved by Board within 90 days of Performance Period start; adjustable for unanticipated events.
• ·Exhibits include full 2026 Corporate Bonus Plan (10.1) and Amendment No. 1 to Okazaki's employment agreement (10.2).

30-03-2026

On March 24, 2026, the Compensation Committee of Graham Corporation's Board of Directors approved annual base salary increases for President and CEO Matthew J. Malone to $600,000 and for VP-Finance, CFO, and Chief Accounting Officer Christopher J. Thome to $400,000. The Committee also increased Malone's target LTIP award for fiscal 2027 to 200% of his base salary and Thome's target Executive Cash Bonus Program award to 70% of his base salary. No other changes to officer positions or departures were reported.

• ·Compensation Committee approvals effective March 24, 2026
• ·Form 8-K filed March 30, 2026

30-03-2026

On March 25, 2026, the Board of Directors of The LGL Group, Inc. approved a modification to the compensatory arrangement for Chief Executive Officer Jason Lamb, effective January 5, 2026, entitling him to an annual base salary of $190,000. This salary is in addition to the previously disclosed $60,000 incentive draw. No other changes were made to Mr. Lamb's compensation arrangements.

• ·Form 8-K filed on March 30, 2026, reporting event dated March 25, 2026.
• ·Previous disclosure in Amendment No. 1 to Form 8-K filed January 9, 2026.

30-03-2026

Inogen, Inc. announced leadership appointments to accelerate growth, including Jason Richardson as CFO effective April 6, 2026, succeeding Michael Bourque who will advise until June 30, 2026; Dominic Hulton as CMO effective April 1, 2026; and Corey Moritz as VP U.S. B2B Sales since March 9, 2026. These executives bring extensive experience from Baxter International ($3B segment), Insulet, and Rhythm Healthcare, with Bourque credited for achieving positive adjusted EBITDA for the first time in four years. The company reaffirmed its Q1 and FY 2026 financial outlook previously issued on February 24, 2026.

• ·Dominic Hulton has over 20 years of experience, including 11 years at Insulet.
• ·Corey Moritz has more than two decades of experience and built six sales forces.
• ·Forward-looking statements subject to risks detailed in 10-K for period ended December 31, 2025.

30-03-2026

On March 26, 2026, the Board of Directors of WEBTOON Entertainment Inc. approved a Housing Assistance Policy for the company's Chief Executive Officer in connection with the CEO's relocation from Korea to the United States for business purposes. The policy provides a fixed annual cash allowance of $250,350, paid on a monthly basis, with eligibility requiring active employment at the time of payment. The full text of the policy is filed as Exhibit 10.1 to this Form 8-K.

• ·Policy approved for CEO relocation of primary residence from Korea to the United States
• ·Housing Assistance Policy filed as Exhibit 10.1

30-03-2026

On March 30, 2026, Charging Robotics Inc. appointed Amir Nardimon, founder and CEO of Deliverz.ai Ltd., and Itay Meroz, director at Formula Systems (1985) Ltd., to its Board of Directors, effective immediately, bringing expertise in AI robotics, software engineering, and financial management. Concurrently, directors Amitay Weiss and Kineret Tzedef resigned for personal reasons, with no disagreements with the company or management. The new directors will receive standard non-executive compensation as detailed in the 2025 Form 10-K, with no related arrangements or disclosable transactions under Item 404(a).

30-03-2026

On March 26, 2026, Universal Health Services, Inc.'s Compensation Committee approved 2026 annual incentive bonus formulae for executive officers under the 2022 Executive Incentive Plan, with targets at 150% of base salary for CEO Marc D. Miller and 100% for others, based on adjusted net income per diluted share and return on capital. A discretionary $1.07 million cash bonus was approved for Executive Chairman Alan B. Miller for 2025. The Committee also awarded time-based RSUs and performance-based PBRSUs to executives under the 2020 Omnibus Stock and Incentive Plan, computed at $185.09 per share.

• ·RSUs vest in four equal annual installments starting on first anniversary of March 26, 2026 grant date.
• ·PBRSUs based on three-year average (2026-2028) Adjusted EBITDA net of NCI; 50% payout at 90% threshold, 200% at 110%+ threshold.
• ·Annual incentives for Sim and Peterson: 25% corporate criteria (adjusted net income per diluted share and return on capital), 75% divisional pre-tax income net of capital cost.
• ·Corporate performance criteria exclude nonrecurring/non-operational items; divisional targets adjustable similarly.

30-03-2026

Reginald T. Jackson, Senior Vice President and Chief Accounting Officer of Entergy Corporation and its operating companies (Entergy Arkansas LLC, Entergy Louisiana LLC, Entergy Mississippi LLC, Entergy New Orleans LLC, and Entergy Texas Inc.), intends to retire effective May 31, 2026. Patrick J. Stack, age 53 and currently Corporate Controller of Entergy Services LLC, will be appointed to succeed him as Senior Vice President and Chief Accounting Officer starting June 1, 2026, with an annual base salary of $356,000 and eligibility for an annual incentive bonus targeted at 45% of base salary. There are no related arrangements, family relationships, or material related party transactions.

• ·Event reported on March 25, 2026; filing dated March 30, 2026.
• ·Mr. Stack held position of Controller, Utility Operations Accounting at Entergy Services LLC from January 2019 to March 2022.
• ·Compensation awards determined via normal annual review process consistent with seniority and responsibility.

30-03-2026

Genasys Inc. (NASDAQ: GNSS) appointed Larry Hagenbuch to its Board of Directors effective March 30, 2026, where he will serve as Chair of the Audit Committee. Mr. Hagenbuch, an operating partner at Crossplane Capital, brings extensive audit, financial oversight, operational, and restructuring experience from prior roles including audit chair at HireQuest (HQI) and Optex Systems, interim C-level positions at Huron Consulting, and positions at GE, GE Capital, and J. Hilburn. CEO Richard Danforth highlighted Hagenbuch's qualifications to support scaling growth amid opportunities like the Puerto Rico Dams Early Warning System project.

• ·Mr. Hagenbuch began career in U.S. Navy as weapons officer on USS Reuben James (FFG-57).
• ·Earned BS in Mechanical and Materials Engineering from Vanderbilt University and MBA from Wharton School at University of Pennsylvania.
• ·Genasys covers more than 155 million people in all 50 U.S. states and over 100 countries worldwide.
• ·References risks including Puerto Rico project funding uncertainties, geopolitical unrest, and need for additional capital in forward-looking statements.

30-03-2026

On March 26, 2026, Unnikrishnan (Unni) Balakrishnan Nambiar resigned as Chief Technology Officer of Aeries Technology, Inc., effective March 31, 2026, to assume a leadership role at the Company's wholly-owned Indian subsidiary, Aeries Technology Group Business Accelerators Private Limited. The Board of Directors appointed Bhisham (Ajay) Khare, the current Chief Executive Officer, Principal Financial Officer, and Director, as Principal Accounting Officer, effective March 31, 2026. No material compensatory arrangements, family relationships, or disclosable transactions under Item 404(a) were entered into with Mr. Khare.

• ·Bhisham (Ajay) Khare, age 48, has served as CEO and Director since February 2025, and Chief Revenue Officer and COO since November 2023 business combination.
• ·Prior to business combination, Mr. Khare was Chief Revenue Officer and COO for the Americas division of Aeries group since 2015.
• ·No family relationships between Mr. Khare and any current or former directors or executive officers.

30-03-2026

Tenet Healthcare Corporation extended the retirement date of Senior Vice President & Controller (Principal Accounting Officer) R. Scott Ramsey to April 30, 2026, from March 31, 2026, with part-time transition services through March 31, 2028. The Company appointed J. Michael Grooms, age 48 and former Senior Vice President, Chief Accounting Officer at Lifepoint Health, Inc., as Senior Vice President & Controller effective April 6, 2026, succeeding Ramsey as Principal Accounting Officer on May 1, 2026. Grooms' compensation includes an annual base salary of $475,000, target cash bonus at 60% of salary, initial RSUs with $500,000 grant date value, a $250,000 sign-on bonus, and relocation benefits.

• ·Mr. Grooms' initial RSUs vest one-half on the second anniversary of the grant date and the other half on the third anniversary.
• ·Recommended 2027 equity award for Mr. Grooms comprised of 50% service-based RSUs and 50% performance-based RSUs.
• ·Event reported on March 25, 2026; filing dated March 30, 2026.

30-03-2026

On March 25, 2026, 4D Molecular Therapeutics, Inc. appointed Kristian Humer as Principal Accounting Officer, effective immediately, succeeding Ashoo Gupta who continues as Vice President, Finance and Controller. Mr. Humer, age 51, has served as the company's Chief Financial Officer and Principal Financial Officer since November 2025. No financial impacts or other changes were disclosed.

• ·Kristian Humer served as CFO at Foghorn Therapeutics, Inc. from April 2024 to November 2025.
• ·Kristian Humer was CFO and Chief Business Officer at Viridian Therapeutics, Inc. from July 2021 to September 2023.
• ·Kristian Humer held various roles at Citigroup Global Markets Inc. from January 2010 to July 2021, most recently Managing Director in Healthcare Investment Banking.
• ·Kristian Humer holds an MBA from Duke University’s Fuqua School of Business and a BA (Hons) in Accounting & Economics from the University of Reading.

30-03-2026

On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors of Cartesian Therapeutics, Inc., notified the company of his intent to resign effective March 31, 2026, to pursue other opportunities. Dr. Kalayoglu served as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee since 2023. His resignation was not due to any disagreement with the company’s operations, policies, or practices.

• ·The report was signed by Carsten Brunn, Ph.D. on March 30, 2026.
• ·Cartesian Therapeutics, Inc. is incorporated in Delaware, with CIK 0001453687 and IRS Employer Identification No. 26-1622110.

30-03-2026

HealthEquity, Inc. (NASDAQ: HQY) appointed William ‘Bill’ Gassen, president and CEO of Sanford Health, to its board of directors effective March 26, 2026, expanding the board to 10 directors with eight independent. Gassen will serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee, bringing expertise in healthcare delivery and financing. The company administers HSAs and other consumer-directed benefits for more than 17 million accounts.

• ·Gassen has served as Sanford Health CEO since November 2020, leading the nation’s largest rural health system.
• ·Prior roles at Sanford Health: chief administrative officer (Jan-Nov 2020), chief human resources officer (Jul 2016-Jan 2020), vice president of human resources integration and corporate services (Oct 2014-Jun 2016), corporate counsel (Feb 2012-Sep 2014).
• ·Gassen holds a bachelor’s degree in criminal justice and J.D. from the University of South Dakota.

30-03-2026

On March 27, 2026, Newton Golf Company, Inc. terminated Greg Campbell as Executive Chairman, Chief Executive Officer, and principal executive officer. The company appointed co-founder Akinobu Yorihiro, age 57, as Interim Chief Executive Officer and principal executive officer, while Brett Hoge was appointed Chairperson of the Board of Directors. Yorihiro's compensation remained unchanged, and there are no family relationships or material interests disclosed.

• ·Akinobu Yorihiro has served as a director and Chief Technology Officer since March 2018.
• ·Yorihiro previously served as Chairman of Nippon Xport Ventures, Inc. (2017-2023), CEO of Yoshimoto Entertainment USA and Bellrock Media (2006-2017), and Corporate M&A Partner at Bingham McCutchen LLP (1993-2006).
• ·No arrangements or understandings pursuant to which Yorihiro was selected as Interim CEO.
• ·Company is an emerging growth company; common stock (NWTG) trades on Nasdaq.
• ·Event reported on Form 8-K filed March 30, 2026.

30-03-2026

Zivo Bioscience, Inc. (OTCQB: ZIVO) announced its Board of Directors' decision to voluntarily delist its common stock and warrants from OTC markets and file Form 15 to deregister with the SEC around March 30, 2026, citing high SEC compliance costs including legal, accounting, and administrative expenses as a significant burden diverting resources from core operations. This will immediately suspend reporting obligations such as Forms 10-K, 10-Q, and 8-K, reducing transparency for investors. Management views deregistration positively to redirect resources toward advancing animal health and nutrition segments and creating long-term stockholder value, though it introduces risks like reduced visibility and market access.

• ·ZIVO engaged in biotech and agtech R&D for human and animal health applications.
• ·Contact: jpayne@zivobioscience.com; IR: (212) 201-6614, tpatel@allianceadvisors.com.
• ·Forward-looking statements include risks such as inability to commercialize products, raise funds, or protect IP.

30-03-2026

Neogen Corporation announced on March 30, 2026, that Amy Rocklin, its Chief Legal and Administrative Officer, will depart effective March 31, 2026. The filing provides no details on the reasons for departure or any named successor. The report was signed by R. Bryan Riggsbee, Chief Financial Officer.

30-03-2026

Terra Innovatum Global N.V. (NKLR) reported the immediate resignation of Guillaume Moyen from all positions, including CFO and executive director, on March 28, 2026. On March 29, 2026, the Board appointed Katherine Williams as executive director and CFO, effective immediately, while she resigned from her prior roles as non-executive director, Board chairperson, and committee memberships; Michael Howard was appointed Board chairperson and Peter Hastings to the Audit Committee. No family relationships or material related party transactions were disclosed beyond a services agreement to be amended.

• ·Katherine Williams has served as director since October 2025; previously CFO of Solestiss LLC (energy developer/consultancy in nuclear/renewables) since April 2025 and CEO/CFO of Framatome Inc. (nuclear engineering) from February 2002 to May 2024; holds B.S. from College of Charleston and MBA from University of Pittsburgh.
• ·Services Agreement with Katherine Williams dated December 10, 2025, provides for Board fees per Remuneration Policy and equity awards; to be amended for new role.
• ·Company trades as NKLR on Nasdaq (Ordinary Shares, par value €0.01); emerging growth company.

30-03-2026

On March 25, 2026, the Board of Directors of Cross Country Healthcare, Inc. approved the appointment of Amiee Hawkins as Chief Operating Officer, effective March 28, 2026. Ms. Hawkins, aged 46, previously served as the company's Chief Solutions and Operations Officer and has held various senior roles since joining in 2014. No new agreements, compensation changes, arrangements, material interests, or family relationships were disclosed.

• ·Ms. Hawkins joined in 2014 as VP of Centralized Services (until 2019), then VP of Shared Services Operations and VP of Nurse and Allied Operations (2019), Division Senior VP of Nurse and Allied Operations (2020-2022), Senior VP of Enterprise Operations (2022-2024), and Chief Solutions Officer (2024-2025).
• ·No arrangement or understanding with any other person for the appointment.

30-03-2026

Cass Information Systems, Inc. (Nasdaq: CASS) announced Eric Giering as the new President of its subsidiary Cass Commercial Bank, effective after Dwight D. Erdbruegger retires in September 2026 following his tenure since July 2018. Under Erdbruegger's leadership, the bank strengthened its market position, expanded business lines, and maintained conservative credit management and strong financial performance. Giering, who joined in 2019 as Director of Commercial Banking, has advanced the bank's strategy, growth, and client relationships while upholding disciplined risk practices.

• ·Cass Commercial Bank founded in 1906 and based in St. Louis.
• ·Giering brings more than three decades of commercial banking experience.
• ·Giering holds a Master of Business Administration in Finance from Central Michigan University and a Bachelor of Business Administration in Finance from Western Michigan University.
• ·Cass Information Systems, Inc. disburses tens of billions of dollars annually on behalf of clients.

30-03-2026

Global Interactive Technologies, Inc. appointed Taehoon Kim as Chief Executive Officer effective March 26, 2026, following his role as Interim CEO since February 2024. There are no changes to his compensation, no arrangements or understandings with other persons regarding the appointment, no family relationships with directors or officers, and no disclosable transactions under Item 404(a) of Regulation S-K.

• ·Company is an emerging growth company.
• ·Common Stock, par value $0.001 per share, trades under GITS on Nasdaq.
• ·Principal executive offices: 160, Yeouiseo-ro, Yeongdeungpo-gu, Seoul, Republic of Korea 07231.

30-03-2026

On March 27, 2026, James S. Cook resigned as Executive Vice President, Human Resources of The Manitowoc Company, Inc., effective March 29, 2026, with transitional employment until the Separation Date of June 19, 2026. The Company entered into a separation agreement providing Mr. Cook with base salary and health insurance benefits during the transition period, but no additional equity or incentive compensation, and post-separation COBRA coverage through September 30, 2026, contingent on a release of claims and compliance. The agreement includes customary release of claims and restrictive covenants, though Mr. Cook is released from certain non-compete and non-solicitation obligations after the Separation Date.

• ·Filing signed by Jennifer L. Paterson on March 30, 2026
• ·Resignation from transitional employment effective June 19, 2026

30-03-2026

Flowers Foods, Inc. announced the departure of Chief Growth Officer Terry Thomas, with the role created in 2023 now dissolved after successfully establishing growth capabilities, which are being integrated into the ongoing business structure. Responsibilities are transitioning to senior leaders, including Chief Brand Officer Mark Courtney, who will report directly to Chairman and CEO Ryals McMullian and assume oversight of retail customer sales, innovation, and revenue management. The changes complement recent operations restructuring and support future growth, with the company reporting 2025 sales of $5.3 billion.

• ·Headquartered in Thomasville, Ga.
• ·Filing date: March 30, 2026

30-03-2026

Champions Oncology, Inc. (Nasdaq: CSBR) announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors on March 30, 2026, to advance its data-driven oncology strategy integrating patient-derived tumor models with molecular and clinical datasets. Dr. Alexander brings expertise from senior roles at Valo Health, Flagship Pioneering, and Foundation Medicine, supporting the company's evolution toward AI-powered analytics for drug discovery and development. Chairman Ronnie Morris highlighted Alexander's alignment with Champions' focus on linking tumor models with multi-omic data to accelerate R&D.

• ·Contact for media inquiries: Gavin Cooper, gcooper@championsoncology.com, +1 (518) 488 9062
• ·Company website: www.championsoncology.com
• ·Data services page: https://www.championsoncology.com/data-ecosystem

30-03-2026

Paul A. Steiner, Corporate Controller and Chief Accounting Officer of Commerce Bancshares, Inc., resigned on March 24, 2026, to pursue other opportunities, with no disagreements on finances, accounting, operations, policies, or practices; he will remain until July 7, 2026, for an orderly transition. Steven A. Brandjord, current Assistant Controller and Director of Tax, was named as his successor, effective May 2026 following Board appointment. In connection with the promotion, Mr. Brandjord receives approximately 2,100 restricted stock units vesting over 4 years.

• ·Mr. Brandjord joined Commerce Bancshares, Inc. in 2014, previously serving as Tax Manager III and Senior Manager in tax at BKD, LLP.
• ·Filing signed by Margaret M. Rowe on March 30, 2026.

30-03-2026

On March 26, 2026, Dr. Susanne Schaffert notified Incyte Corporation of her resignation from the Board of Directors, effective April 15, 2026. The resignation was not due to any disagreement with the Company's operations, policies, or practices. The Board expressed thanks for her contributions since joining in 2022.

• ·Filing submitted on March 30, 2026, reporting event of March 26, 2026

30-03-2026

Trustmark Corporation (NASDAQGS:TRMK) and Trustmark Bank announced that Thomas C. Owens, currently Executive Vice President and CFO, will become Chief Operating Officer of Trustmark Bank effective May 1, 2026. Joseph E. Bond will succeed Owens as Treasurer and Principal Financial Officer of Trustmark Corporation and Executive Vice President and CFO of Trustmark Bank on the same date. CEO Duane A. Dewey praised both executives for their extensive experience in finance, capital management, and leadership at regional banks.

• ·Thomas C. Owens, 62, joined Trustmark in 2013 with 13-year tenure; previously at Webster Financial, Wachovia, Keycorp, Banc One.
• ·Joseph E. Bond, 63, previously Corporate Treasurer at Texas Capital Bancshares since 2021; experience at BBVA USA, Webster Bank, Huntington Bancshares, MNC Financial.
• ·Owens holds BS in Business Administration and Finance from The Ohio State University and MBA in Finance from Winthrop University.
• ·Bond holds BS in Business Administration (Economics and Finance) from University of Pittsburgh (1986).
• ·Trustmark operates in Alabama, Florida, Georgia, Mississippi, Tennessee, and Texas.
• ·Investor contacts: Thomas C. Owens (601-208-7853), F. Joseph Rein, Jr. (601-208-6898); Media: Melanie A. Morgan (601-208-2979).

30-03-2026

On March 27, 2026, Beneficient held its 2026 annual meeting of stockholders with 91.7% of voting power present, where shareholders reelected Class A directors Peter T. Cangany, Patrick J. Donegan, and Karen J. Wendel, ratified Weaver and Tidwell, LLP as independent auditors for the fiscal year ending March 31, 2026, and approved an amendment to the 2023 Long Term Incentive Plan to increase shares of Class A common stock reserved for awards. All three proposals passed with overwhelming majorities, including over 97% approval for the LTIP amendment.

• ·Record date for Annual Meeting: February 13, 2026
• ·Proposal 1 withheld votes: Peter T. Cangany (363,006), Patrick J. Donegan (171,026), Karen J. Wendel (170,777)
• ·Proposal 2: 1,286 votes against, 11 abstentions
• ·Proposal 3: 377,771 votes against, 7 abstentions
• ·LTIP Amendment effective March 27, 2026; full text in Exhibit 10.1